Predictors of PSP disease progression

Progressive Supranuclear Palsy (PSP) is a rare disorder related to Parkinson's disease and Frontotemporal Dementia affecting approximately 2-3/100,000 persons in the US. It is a neurological disease that causes impaired eye movements, speech, balance and falls and rapidly progresses to disability and death. There are currently no treatments for PSP and very few studies using patient reported outcomes measures in PSP. The PSP- Quality of Life scale (PSP-QoL) was first published in 2006, however there have been no studies looking at how the scale changes over time. Importantly, the PSP-QoL has not been compared to the validated PSP Rating Scale (PSPRS, Golbe 2007) except in a small single center cross-sectional cohort study. Validating the PSP-QoL as a patient-reported outcome measure would be extremely important for developing new treatments for this disease.